Clinical Trial Update: Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients [Phase 1, Phase 2]

View source ↗

Summary

This document provides a status update on an ongoing Phase 1/2 trial evaluating allogeneic PB103 natural killer (NK) cell therapy in non-small cell lung cancer,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PB103 NK Cells

Snippet

Sponsor: Precision Biotech Taiwan Corp. | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING